Clinical Research Article

Cognitive and Motor Outcome in Patients with Early-Detected Central Congenital Hypothyroidism Compared with Siblings

Jolanda C. Naafs,1,2 Jan Pieter Marchal,3 Eric Fliers,2 Paul H. Verkerk,4 Michiel A.J. Luijten,3,5 Anita Boelen,6 A.S. Paul van Trotsenburg,1,* and Nitash Zwaveling-Soonawala1,*

1Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, department of Pediatric Endocrinology, Amsterdam, The Netherlands; 2Amsterdam UMC, University of Amsterdam, department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology & Metabolism, Amsterdam, The Netherlands; 3Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Psychosocial Department, Amsterdam, The Netherlands; 4TNO, Department of Child Health, 2301 CE Leiden, The Netherlands; 5Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health research institute, Amsterdam, The Netherlands; and 6Endocrine Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

ORCiD numbers: 0000-0003-3787-0811 (J. C. Naafs); 0000-0001-8048-9050 (E. Fliers); 0000-0001-8016-2859 (M. A.J. Luijten); 0000-0002-4994-2918 (A. Boelen); 0000-0002-9677-7441 (A.S. P. van Trotsenburg); 0000-0003-0318-5541 (N. Zwaveling-Soonawala).

*The authors contributed equally.

Abbreviations: CH, congenital hypothyroidism; FSIQ, full-scale intelligence quotient; FT4, free thyroxine; MPHD, multiple pituitary hormone deficiencies; PSIS, pituitary stalk interruption syndrome; SOD, septo-optic dysplasia; TBG, thyroxine-binding globulin; TSH, thyrotropin.

Received: 9 October 2020; Editorial Decision: 25 November 2020; First Published Online: 3 December 2020; Corrected and Typeset: 4 January 2021.

Abstract

Context: Early treatment of primary congenital hypothyroidism (CH) prevents irreversible brain damage. Contrary to primary CH, outcome studies on central CH are scarce. Most patients with central CH have multiple pituitary hormone deficiencies (MPHD); these patients are also at risk for neonatal hypoglycemia.

Objective: To assess cognitive and motor outcome in patients with early-treated central CH detected by the Dutch neonatal screening.

Methods: In this cross-sectional study, primary outcome full-scale intelligence quotient (FSIQ) was measured in patients with MPHD and patients with isolated central CH born between January 1, 1995, and January 1, 2015, with siblings as controls. Secondary outcomes were intelligence test subscales and motor function. Linear mixed models were used to compare both patient groups and siblings, followed by post hoc tests in case of significant differences.

Results: Eighty-seven patients (52 MPHD; 35 isolated central CH) and 52 siblings were included. Estimated marginal means for FSIQ were 90.7 (95% CI 86.4-95.0) in patients with MPHD and 98.2 (95% CI 93.0-103.5) in patients with isolated central CH. While patients with...
MPHD scored lower FSIQs than siblings (mean difference –7.9 points, 95% CI –13.4 to –2.5; \( P = .002 \)), patients with isolated central CH did not. Processing speed was lower in both patient groups than in siblings (mean differences –10.5 and –10.3 points). Motor difficulties occurred significantly more often in patients (33%) versus siblings (5%; \( P = .004 \)).

**Conclusion:** In early-treated central CH, FSIQ is comparable with siblings in patients with isolated central CH, while patients with MPHD have a significantly lower FSIQ. This may be explained by disease-specific consequences of MPHD, such as neonatal hypoglycemia and more severe hypothyroidism.

**Key Words:** congenital hypothyroidism, central hypothyroidism, congenital hypopituitarism, neonatal screening, cognitive outcome, IQ

Thyroid hormone is essential for normal pre- and postnatal brain development. Since early treatment of children with congenital hypothyroidism (CH) prevents irreversible brain damage (1), this condition has been included in many neonatal screening programs worldwide since the 1970s. When treated early, the cognitive outcome of children with primary CH improves substantially. This has been extensively reported in previous literature, and the majority of early-treated patients now obtain normal or near-normal IQ scores (2, 3). The objective of most neonatal screening programs is to detect primary (thyroidal) CH, the most common form of CH (4). Central CH, caused by insufficient hypothalamic–pituitary stimulation of the thyroid gland, is much less common, with a prevalence of 1:16,000 (5). While it fulfills the criteria for disease screening, central CH is only rarely included in neonatal screening programs (4, 6).

Counterarguments for central CH screening are the presumed mild character of the hypothyroidism, and the assumption that patients are detected early enough by clinical signs of multiple pituitary hormone deficiencies (MPHD). MPHD are present in the majority of patients with central CH (7). In previous studies, both arguments were disproved: more than half of patients with central CH have moderate to severe hypothyroidism, and clinical detection usually occurs far beyond the neonatal period (8-10). In a recent study among patients with early-detected central CH, including patients with isolated disease as well as patients with MPHD, we found that the diagnosis was seldom made based on clinical signs, even though 66% of these patients had been hospitalized in the first week of life (11). Instead, 95% were diagnosed only after the notification of an abnormal neonatal screening result. This emphasizes that clinical diagnosis is neither straightforward nor reliable.

While most screening programs are thyrotropin (TSH)-based, central CH detection requires a thyroxine (T4) or free T4 (FT4) measurement. Since 1995, the Dutch neonatal screening program has consisted of a 3-step approach, with T4 measurement as the first step in all neonates, TSH measurement in the lowest 20% of T4 concentrations, and thyroxine-binding globulin (TBG) measurement in the lowest 5%. This approach effectively detects primary and central CH. TBG measurement prevents false-positive results due to TBG deficiency (5). Failure to detect central CH early is especially worrying for patients with MPHD. In our previous study 96% of patients with MPHD had growth hormone deficiency, and 88% had central adrenal insufficiency (11). With these hormone deficiencies, patients with MPHD are at risk for severe hypoglycemia and thus for brain damage and cognitive impairment (12, 13).

The most important argument in favor of screening for central CH remains an expected improvement in cognitive outcome after early treatment (6). In a recent systematic review, we showed that sufficiently large studies on cognitive outcome in patients with central CH are lacking (14). We identified 6 studies that measured full-scale intelligence quotient (FSIQ), including 30 patients in total (27/30 MPHD). FSIQs were shifted towards lower values with 10% of patients having an FSIQ <70 (below –2 SD in the general population) but the included studies were small, heterogeneous, and possibly suffered from selection bias, so that results should be interpreted with caution (14).

The objective of the current study was to assess cognitive and motor outcome in a 20-year cohort of patients with early-detected central CH, including both patients with isolated central CH and patients with MPHD. Primary outcome was FSIQ; secondary outcomes were intelligence test subscales, motor function, and attending special education.

**Materials and Methods**

**Participants**

All patients with central CH detected by neonatal screening in The Netherlands are registered in a national database maintained by the Netherlands Organization for Applied Scientific Research. Permission to access the database was obtained from the Privacy Committee of the Dutch CH Screening Board. We selected patients born between January 1, 1995, and January 1, 2015. The starting year was in accordance with the last modification of the neonatal screening program, that is, adding TBG as the third...
measurement (5). The end date ensured patients would be ≥3 years old, which is considered the youngest age to reliably conduct the selected intelligence tests (15).

Patients were recruited through their current treating physician (11). Patients with a severe syndrome were included or excluded based on their ability to complete an intelligence test; this was mainly judged based on their ability to communicate. Patients with the following syndromes were excluded: Kabuki syndrome, KAT6A syndrome, trisomy 15, muscle–eye–brain disease, and severe septo-optic dysplasia (SOD). One patient with a mild phenotype of SOD was included (11).

For each included patient 1 unaffected sibling of at least 3 years old, sharing both biological parents with the patient, was included as control. In case of multiple siblings, the sibling with the smallest age difference was included, with preference given to older siblings over younger siblings. In families with 2 eligible patients, both were included as patients. Whereas male patients with isolated central CH caused by (X-linked) TBL1X or IRS4 variants were included, female siblings with these variants, namely carriers, were not. This is because carriers are reported to have lower plasma FT4 concentrations, and it remains unclear whether this represents disease or reflects an altered individual “set point” (16).

Demographic and clinical data collection
Medical charts were obtained to collect clinical data, and parents completed an online sociodemographic questionnaire. FT4 measurement was performed in all patients within a time span of 90 days before or after the cognitive assessment. Genetic testing was performed in patients with isolated central CH as part of our previous study (11). As reported in this previous study, we did not perform genetic testing in patients with MPHD because of an anticipated low mutation yield, especially in patients with nonsyndromic MPHD (11, 17).

Outcome assessment
Cognitive function
Cognitive assessment was performed at the study hospital (Amsterdam UMC, location AMC; 74 patients/47 siblings) or upon request at the patients’ local hospital (13 patients/5 siblings) between June 2017 and December 2019. Tests were performed in the morning by a pediatric neuropsychologist (J.P.M.), a physician (J.C.N.), or a psychology student trained by the pediatric neuropsychologist. Although assessors were not involved in clinical care for the patients, they were not formally blinded for the participants’ disease status: participants were not asked to conceal their disease status but were also not encouraged to talk about it. We used the most recent Dutch Wechsler scales available at the start of the study: the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III-NL) for participants <6 years, the Wechsler Intelligence Scale for Children (WISC-III-NL) for participants 6 to 16.9 years old, and the Wechsler Adult Intelligence Scale (WAIS-IV-NL) for participants ≥17 years. When a participant underwent a Wechsler test within the previous 12 months (n = 4), the first score was obtained rather than retesting, to prevent an inflated score due to a practice effect (18). The mean population norm score for FSIQ, as well as for subscales, is 100 with a SD of 15.

By design, reported subscales differ between the used intelligence tests. WPPSI-III- and WISC-III–specific subscales are verbal and performance IQ. WAIS-specific subscales are verbal comprehension, perceptual reasoning, and working memory. Processing speed is reported in all tests, except for the WPPSI in participants under 4 years of age. Attendance of special education was assessed through a questionnaire. In The Netherlands, education for children with learning disabilities is mostly integrated in regular education, but special education is available for children with severe learning disabilities or other special needs.

Motor function
Parents were asked to complete the Motor Assessment Battery for Children-2 (MABC-2) checklist, developed to screen 5- to 13-year-old children in primary education for motor difficulties (19). The numerical outcome is compared with an age-specific norm score, using the 85th and 95th percentile as cut-offs to differentiate between normal (“green”), and abnormal scores (“orange” if >85th percentile or “red” if >95th percentile). MABC-2 scores ≥85th percentile were considered abnormal, that is, indicative for motor difficulties.

Data on age at attainment of motor milestones (sitting, standing and walking independently) and need for physical therapy for delayed motor development were collected from medical charts and by consulting parents.

Statistical analysis
Clinical characteristics were compared between patient groups (MPHD vs isolated central CH) using the chi-squared test or Fisher’s exact test for dichotomous variables, and the Student’s t test for normally distributed continuous variables. For non-normally distributed continuous variables the Mann–Whitney U test was used. Primary outcome FSIQ and continuous secondary outcomes were compared between the 2 patient groups and siblings using a linear mixed model based on maximum likelihood estimation. A linear mixed model accounts for the fact that patient and sibling data are not independent,
and facilitates the use of data from all patients, regardless of the presence of an eligible sibling. A random intercept was constructed for each family. Endocrine status (MPHD, isolated central CH, or healthy) was included as a fixed factor. Since all tests yielded age-specific norm scores, age was not added to the model. By using a sibling control group, confounding factors shared by patients and siblings were controlled for. Significant differences identified through linear mixed models were explored in post hoc analysis using Tukey’s range test. To assess the association between severity of hypothyroidism and FSIQ, pretreatment FT4 concentration was added to the FSIQ model. In a separate analysis, the FT4 concentration during the IQ assessment was added to model for FSIQ as well, to determine whether the current FT4 concentration affected FSIQ. The fit of these models was compared with the model for FSIQ with the likelihood ratio test. Pearson’s correlation coefficient was calculated to assess the relationship between pretreatment FT4 and FSIQ, and FT4 and processing speed. Proportions of dichotomous outcomes were compared using McNemar’s test. Proportions of abnormal MABC-2 scores were compared using the z-test for partially paired samples, as the MABC-2 checklist is validated for ages 5 to 13 only, thus rendering a partially paired sample (20). The level of statistical significance was set at $P < .05$. Analyses were performed with RStudio version 3.6.1 (2019-07-05), using packages lme4, emmeans, partiallyoverlapping and ggplot (20, 21).

**Ethical aspects**

The study protocol was approved by the ethics committee of Amsterdam UMC, location AMC. All participants gave their informed consent. Written permission was obtained from all patients ≥12 years and from both parents (where applicable) for patients younger than 18 years.

**Role of funding source**

Support for this investigator-initiated study was provided by Pfizer (tracking number WI219179). Pfizer was not involved in patient recruitment, data collection, data analysis, or preparation of the manuscript. Pfizer reviewed the manuscript prior to submission for publication.

**Results**

From the nationwide database, 133 patients with central CH were identified, of whom 7 were excluded because of a severe syndrome (11). Of the remaining patients, 3 had emigrated, 1 was untraceable, and 35 declined participation in the cognitive assessment, yielding 87 patients and 52 siblings, originating from 84 families. One patient with mild SOD was included; 3 patients with severe SOD and 1 patient with mild SOD and severe visual impairment were excluded. No siblings were excluded because of a severe syndrome. From 3 families, 2 patients (and no siblings) were included.

Table 1 summarizes the perinatal and sociodemographic characteristics of participants, which were comparable between patients and siblings. A male predominance was seen among patients; this was not unexpected since isolated central CH is associated with X-linked genes (16, 22). Characteristics of both patient groups are summarized in Table 2, which includes the genetic etiology of isolated central CH for 27 out of 35 cases (15 IGSF1, 5 IRS4, 5 TBL1X, 1 TRHR, 1 TSHB).

### Table 1. Perinatal and sociodemographic characteristics of participating patients with central congenital hypothyroidism (CH) and sibling controls

|                         | Patients (n = 87) | Siblings (n = 52) |
|-------------------------|-------------------|-------------------|
| Male (%)                | 68 (78)           | 26 (50)           |
| Age (years)             | 11.5 (7.6-17.9)   | 12.7 (7.9-15.6)   |
| Gestational age (weeks) | 40.1 (38.4-41.4)  | 39.5 (38.0-40.8)  |
| Birthweight (g)         | 3391 ± 666        | 3201 ± 666        |
| Birthweight SDS         | –0.14 ± 1.2       | –0.14 ± 1.1       |
| Apgar score <6 at 5 minutes of age | 5 (6)         | 1 (2)             |

**Maternal education**

|                         | Patients (n = 87) | Siblings (n = 52) |
|-------------------------|-------------------|-------------------|
| Lower                   | 22 (25)           | 12 (23)           |
| Intermediate            | 31 (36)           | 22 (42)           |
| Higher                  | 30 (35)           | 14 (27)           |
| Not specified           | 4 (5)             | 4 (8)             |

**Paternal education**

|                         | Patients (n = 87) | Siblings (n = 52) |
|-------------------------|-------------------|-------------------|
| Lower                   | 23 (26)           | 13 (25)           |
| Intermediate            | 25 (29)           | 16 (31)           |
| Higher                  | 28 (32)           | 17 (33)           |
| Not specified           | 11 (13)           | 6 (12)            |

**Paid parental employment**

|                         | Patients (n = 87) | Siblings (n = 52) |
|-------------------------|-------------------|-------------------|
| Yes                     | 63 (72)           | 41 (79)           |
| No                      | 10 (12)           | 4 (8)             |
| Not specified           | 14 (16)           | 7 (14)            |

Numbers represent n (%), median (interquartile range) or mean (± SD). Abbreviation: SDS, standard deviation score.

The level of education was classified as lower, intermediate or higher following the classification of Statistics Netherlands (CBS): “lower education” contains primary education, lower vocational education and general secondary education at junior level, “intermediate education” contains general secondary education at senior level and intermediate vocational education, and “higher education” comprises higher professional education and university education.
FT4 concentration was within target range in 80 patients (92%), above the upper limit of the reference interval in 5 patients (23-25.9 pmol/L) and below the lower limit in 2 patients (8.4 and 10 pmol/L).

Cognitive outcome
Mean FSIQ was 93.8 ± 17.9 in all patients with central CH and 99.2 ± 14.0 in siblings (Fig. 1). Patients and siblings were compared using linear mixed models, taking into account the patient’s endocrine status (MPHD or isolated central CH). Mean FSIQ in patients with MPHD was 90.7 (95% CI 86.4-95.0), compared with 98.2 (95% CI 93.0-103.5) in patients with isolated central CH, and 98.6 (95% CI 94.5-102.8) in siblings (Table 3). Post hoc analysis showed that patients with MPHD scored 7.9 points lower than siblings (95% CI −13.4 to −2.5, P = .002), and 7.5 points lower than patients with isolated central CH (95% CI −15.1 to 0.01, P = .05; Table 4). Adding pretreatment FT4, as indicator of severity of hypothyroidism, to the model did not improve the fit of the model (P = .18). If assessed outside of the model, a weak positive correlation between pretreatment FT4 and FSIQ was found (r = 0.22; P = .04). Adding the FT4 concentration measured at the time of the assessment to the model for FSIQ did not improve the model fit (P = .88).

An FSIQ <85, that is, <=1 SD in the general population, was seen in 28 (52%) patients versus 8 (15%) siblings (P = .05). Eight patients (9%), but no sibling controls, had an FSIQ <70, <=2 SD in the general population (P = .04).

Processing speed was significantly lower in both patient groups when compared with siblings, with a similar difference in patients with MPHD and patients with isolated central CH, scoring on average 10.5 and 10.3 points lower than siblings (Table 4). Among patients, a weak correlation between pretreatment FT4 and processing speed was seen (r = 0.22; P = .04).

Ten patients (11%) and 4 siblings (8%) attended special education. Patients with MPHD attended special education more frequently than patients with isolated central CH (9/52 vs 1/35, P = .04). Only 6 out of 9 patients with MPHD in special education had a participating sibling; pairwise analysis showed no significant difference between patients and siblings (P = .68). Comparisons of primary and secondary outcomes between groups did not change when patients with a FT4 concentration outside the target range during the cognitive assessment were excluded. FSIQ and additional subscales did not differ between patients with and without a participating sibling (data not shown).

### Table 2. Disease characteristics of patients with multiple pituitary hormone deficiencies (MPHD) and isolated central congenital hypothyroidism (CH)

|                         | MPHD patients (n = 52) | Isolated central CH patients (n = 35) | P value |
|-------------------------|------------------------|---------------------------------------|---------|
| Pretreatment FT4 (pmol/L) | 8.8 ± 2.0              | 10.4 ± 2.3                            | <.001   |
| CH severity             |                        |                                       |         |
| Mild (FT4 ≥ 10 pmol/L)  | 16 (31)                | 22 (63)                               | .006    |
| Moderate (FT4 5-10 pmol/L) | 35 (67)               | 12 (34)                               | .005    |
| Severe (FT4 < 5 pmol/L) | 1 (2)                  | 1 (3)                                 | 1       |
| Age at treatment initiation (day of life) | 17 (14.8-21.5) | 21 (16-28)                            | .10     |
| FT4 concentration during assessment | |                                       |         |
| Within RI               | 47 (90)                | 33 (94)                               | .70     |
| Above upper limit of RI | 5 (10)                 | 0 (0)                                 | .08     |
| Below lower limit of RI | 0 (0)                  | 2 (6)                                 | .16     |
| Additional pituitary hormone deficiencies | |                                       |         |
| Growth hormone deficiency | 50 (96)             | 1 (3)a                                | NA      |
| Adrenocorticotropin deficiency | 46 (88)       | NA                                     | NA      |
| Neonatal hypoglycemia   | 28 (55) (n = 51)       | 5 (15) (n = 34)                       | <.001   |
| Lowest glucose level (mmol/L) | 1.2 ± 0.8^b (n = 26) | 2.1 ± 0.5                             | .02     |
| Gonadotropin deficiency | 19 (79)b              | NA                                     | NA      |
| MRI pituitary findings in patients with MPHD | |                                       |         |
| Pituitary malformation within the spectrum of PSIS | 46 (88) | NA                                     |         |
| No abnormalities         | 3 (6)                  |                                       |         |
| MRI not performed or failed | 3 (6)                |                                       |         |
| Gene variants in patients with isolated central CH | |                                       |         |
| IGSF1                   | 15 (43)                |                                       |         |
| IRS4                    | 5 (14)                 |                                       |         |
| TBL1X                   | 5 (14)                 |                                       |         |
| TRHR                    | 1 (3)                  |                                       |         |
| TSHB                    | 1 (3)                  |                                       |         |
| No gene variants identified | 6 (17)             |                                       |         |
| Genetic analysis not performed | 2 (6) |                                       |         |

Numbers represent n (%), mean (± SD) or median (interquartile range). Malformations within the PSIS spectrum include anterior pituitary hypoplasia, an interrupted pituitary stalk and an ectopic posterior pituitary. Abbreviations: FT4, free thyroxine; MRI, magnetic resonance imaging; PSIS, pituitary stalk interruption syndrome.

^aPartial growth hormone deficiency in one patient with IGSF1 deficiency syndrome.

^bN = 24 with final outcome available, 28 not known yet.

Motor outcome
The MABC-2 checklist was completed for 39 patients (24 MPHD, 15 isolated central CH) and 21 siblings, and indicated motor difficulties in 5 patients with isolated central CH (33%), 8 MPHD patients (33%), and 1 sibling (5%). Motor difficulties were seen more often in patients than
in siblings (P = .004). In addition, delayed motor development requiring physical therapy was present in 30 patients (34%) and 10 siblings (19%; P = .03). Because not all parents could remember when motor milestones were reached, data on motor milestones are not available for all patients. Milestone “walking independently” was reached significantly later by patients than siblings; this age difference was mainly caused by the difference between patients with MPHD and siblings (Table 4).

**Discussion**

The Netherlands has a long history of neonatal screening for both primary and central CH. In this study, which included the largest group of patients with early-treated central CH to date, we show a normal FSIQ in patients with isolated central CH, but a significantly lower FSIQ in patients with MPHD than in siblings. It remains unknown what these outcomes would be without neonatal detection, but it is likely that neonatal screening prevents prolonged thyroid hormone shortage and its consequences on brain development. In patients with MPHD, early diagnosis also prevents the consequences of additional pituitary hormone deficiencies, such as ongoing hypoglycemia, and thus aggravation of cognitive impairment. The current study cannot answer the question whether neonatal screening for central CH prevents cognitive impairment. To further investigate the role of early detection, studies on cognitive outcome in patients with late-detected central CH are necessary.

There are several possible explanations for the observed lower FSIQs in patients with early-detected MPHD; the

---

**Table 3. Cognitive and motor outcomes in patients with multiple pituitary hormone deficiencies (MPHDs) and patients with isolated central congenital hypothyroidism (CH), compared with healthy siblings**

| Outcome                          | MPHD patients (n = 52) | Isolated central CH patients (n = 35) | Siblings (n = 52) | P-value |
|----------------------------------|------------------------|--------------------------------------|-------------------|---------|
| Mean FSIQ                         | 90.7 (86.4-95.0)       | 98.2 (93.0-103.5)                    | 96.6 (94.5-102.8) | 0.002   |
| Processing speed                  | 91.4 (86.1-96.7)       | 91.4 (89.2-103.5)                    | 99.6 (94.5-106.0) | <.001   |
| WPPSI/WISC: Verbal IQ             | 89.4 (83.9-94.0)       | 89.1 (87.9-94.0)                     | 96.1 (90.6-101.6) | <.001   |
| WPPSI/WISC: Performance IQ        | 94.4 (88.7-99.7)       | 94.1 (89.1-99.1)                     | 104.0 (99.5-114.2)| <.001   |
| WAIS: Verbal comprehension        | 91.0 (82.2-99.7)       | 90.1 (81.9-99.1)                     | 105.5 (95.4-114.2)| <.001   |
| WAIS: Perceptual reasoning        | 89.9 (82.3-97.5)       | 94.9 (87.1-102.8)                    | 104.2 (99.7-114.9)| <.001   |
| WAIS: Working memory              | 8.9 (7.6-9.4)          | 8.5 (7.6-9.5)                        | 10.0 (9.8-11.4)   | 0.02    |
| Milestone: sitting independently  | 8.9 (7.6-9.6)          | 9.0 (8.7-9.8)                        | 11.0 (10.0-11.9)  | 0.02    |
| Milestone: standing (months)      | 11.7 (11.0-12.5)       | 14.9 (13.0-15.9)                     | 15.9 (15.0-16.7)  | 0.02    |
| Milestone: walking independently  | 15.3 (15.0-15.6)       | 14.9 (13.9-15.1)                     | 14.9 (13.9-16.0)  | 0.02    |
| Milestone: walking independently  | 15.3 (15.0-15.6)       | 14.9 (13.9-15.1)                     | 14.9 (13.9-16.0)  | 0.02    |

Data are presented as mean ± SD, median (range) or n (%). P-values derived from linear mixed models, except when indicated otherwise. Abbreviations: CI, confidence interval; FSIQ, full-scale intelligence quotient; WAIS, Wechsler Adult Intelligence Scales; WISC, Wechsler Intelligence Scale for Children; WPPSI, Wechsler Preschool and Primary Scale of Intelligence. Subscales with different numbers of participants (patients/siblings) due to use of age-appropriate tests; processing speed (85/50); verbal and performance IQ (60/42) and WAIS subscales (26/10). Motor milestones with different number of participants (patients/siblings) due to missing data: sitting (63/37); standing (70/36) and walking independently (83/45).

---

Figure 1. Distribution of full-scale IQ among 87 patients with central congenital hypothyroidism (CH), comprising 35 with isolated central CH and 52 with multiple pituitary hormone deficiencies (MPHD), compared with sibling controls (n = 52). Boxes represent mean full-scale IQ with upper and lower box limits representing ± 1 SD. The horizontal black reference line displays mean full-scale IQ in the general population, with the grey area representing ± 1 SD.
first is the presence of additional pituitary hormone deficiencies in patients with MPHD. Untreated growth hormone deficiency and central adrenal insufficiency can cause neonatal hypoglycemia which was indeed frequently documented (see Table 2). This may have resulted in neurological deficits, such as impaired executive function and visual motor function (13). A second explanation may be found in the degree of hypothyroidism. Based on the pretreatment FT4 concentration 69% of patients with MPHD had moderate to severe hypothyroidism, opposed to only 37% of patients with isolated central CH. Previous studies in patients with primary CH have shown a relationship between pretreatment (F)T4, and FSIQ or obtained educational level (23-25). In general, cognitive outcomes are normal in patients with early-treated mild or moderate primary CH while developmental problems may occur in patients with severe primary CH, despite early treatment (2, 3, 6, 24). However, pretreatment FT4 concentration was not significantly associated with FSIQ in the linear mixed model. This might be due to the small group sizes or various ages in days at which FT4 was measured, but may also indicate that the degree of hypothyroidism is not the main reason for the lower FSIQs in patients with MPHD. A third explanation for the lower FSIQs may be sought in the pituitary anomalies seen in almost all patients with MPHD, specifically, features of pituitary stalk interruption syndrome (PSIS; Table 2). PSIS, a midline brain anomaly, is considered to be at the mild end of the holoprosencephaly spectrum. Developmental delay in PSIS has not been studied extensively but has been described in some patients (26, 27). Since we studied early-treated patients it is possible that the cognitive impairment may be due partly to the brain anomaly itself.

Table 4. Post hoc analyses for differences in full-scale IQ, performance IQ, processing speed, and motor milestone walking independently among patients with multiple pituitary hormone deficiencies (MPHDs), patients with isolated central congenital hypothyroidism (CH), and siblings

|                               | Mean change in score | Standard Error (SE) | Lower limit of 95% CI | Upper limit of 95% CI | P value |
|-------------------------------|---------------------|---------------------|-----------------------|----------------------|---------|
| **Full-scale IQ**             |                     |                     |                       |                      |         |
| Isolated central CH vs siblings | –0.4                | 2.8                 | –7.0                  | 6.3                  | 1       |
| MPHD vs siblings              | –7.9                | 2.3                 | –13.4                 | –2.5                 | .002    |
| MPHD vs isolated central CH   | –7.5                | 3.2                 | –15.1                 | 0.02                 | .05     |
| **Processing speed**          |                     |                     |                       |                      |         |
| Isolated central CH vs siblings | –10.3               | 3.2                 | –17.9                 | –2.8                 | .004    |
| MPHD vs siblings              | –10.5               | 2.8                 | –17.0                 | –3.9                 | <.001   |
| MPHD vs isolated central CH   | –0.1                | 3.4                 | –8.3                  | 8.0                  | 1       |
| **WPPSI/WISC: Performance IQ**|                     |                     |                       |                      |         |
| Isolated central CH vs siblings | –3.8                | 3.0                 | –11.0                 | 3.5                  | .43     |
| MPHD vs siblings              | –10.8               | 2.8                 | –17.5                 | –4.1                 | <.001   |
| MPHD vs isolated central CH   | –7.0                | 3.6                 | –15.5                 | 1.5                  | .13     |
| **WAIS: Perceptual reasoning**|                     |                     |                       |                      |         |
| Isolated central CH vs siblings | –5.5                | 7.4                 | –24.0                 | 13.1                 | .74     |
| MPHD vs siblings              | –12.6               | 5.3                 | –26.2                 | 1.1                  | .08     |
| MPHD vs isolated central CH   | –7.1                | 7.9                 | –26.4                 | 12.3                 | .64     |
| **Motor milestone: walking independently (age in months)** | | | | | |
| Isolated central CH vs siblings | 0.7                 | 0.7                 | –0.9                  | 2.2                  | .56     |
| MPHD vs siblings              | 1.6                 | 0.6                 | 0.2                   | 3.0                  | .02     |
| MPHD vs isolated central CH   | 0.9                 | 0.7                 | –0.7                  | 2.6                  | .37     |

Abbreviations: WAIS, Wechsler Adult Intelligence Scales; WISC, Wechsler Intelligence Scale for Children; WPPSI, Wechsler Preschool and Primary Scale of Intelligence.
is little effect of the presence of additional pituitary hor-
tWEEN processing speed and hypothyroidism, while there
affected similarly, we hypothesize there is a relationship be-
in early-treated patients (31). Because both groups were
cessing speed may be due to impaired myelination, even
of oligodendrocytes before and after birth, a lower pro-
roid hormone plays an important role in the differentiation
primary CH, although not consistently (2, 31). Since thy-
speed has also been reported in patients with early-detected
psychomotor development and postnatal hypothyroidism affects cerebellar development,
and this mechanism is thought to be the origin of motor
deficits in primary CH (32). Our results suggest that the
function might be affected in a similar way in central CH.

Processing speed and motor function
Processing speed is an FSIQ component which measures
the speed with which relatively simple visual motor tasks
are performed (30). The lower processing speed in both pa-
tient groups compared with siblings was especially remark-
able for patients with isolated central CH, who have an
otherwise normal cognitive outcome. A lower processing
speed has also been reported in patients with early-detected
primary CH, who exhibit motor deficits despite early detec-
tion (14, 23, 24). Early postnatal hypothyroidism affects cerebellar development,
and this mechanism is thought to be the origin of motor
deficits in primary CH (32). Our results suggest that motor
function might be affected in a similar way in central CH.

This study has several strengths. We present cognitive
testing results of the largest group of patients with cen-
tral CH studied to date. Almost all patients with MPHD
had PSIS, creating a homogeneous group of patients, and
almost all patients with isolated central CH had a genet-
ically confirmed diagnosis. By using a nationwide cohort,
selection bias was minimized compared to a single center
study, and the included siblings represent an ideal control
group. A limitation of our study was that the checklist used
to assess motor outcome was only suitable for a part of
the patients. This led to a relatively small group for whom
motor outcome could be reported. In addition, the use of a
checklist is considered less reliable than an objective motor
assessment. In the interest of time, we did not perform such
an assessment, but based on our findings we would sug-
gest including it in future studies. The exclusion of syn-
dromic patients from cognitive testing can be considered
both a strength and a limitation. While this creates a more
homogeneous patient group, and rules out syndromes as a
cause of cognitive impairment, it leaves cognitive outcome
in syndromic patients unexplored.

To date, central CH is the only pituitary hormone de-
ciciency accessible for neonatal screening, which can be
performed cost-effectively (5). Comparison of cognitive
outcome in early and late-detected patients will provide the
final answer to the question whether screening for central
CH should be implemented worldwide. This will require
international collaboration in order to collect a sufficiently
large group of late-detected patients. For a comparable
study group of patients with MPHD, studies will prefer-
ably focus on patients with MPHD with PSIS, which could
be achieved by setting up an international registry for this
rare disorder.

Acknowledgments
The authors would also like to thank Brenda Wiedijk (Amsterdam
UMC, location AMC) for her help with patient recruitment and col-
mecation of the medical charts.

Financial Support: NZS has received a grant from Pfizer to sup-
port this investigator-initiated study (tracking number W1219179).
Pfizer was not involved in patient recruitment, data collection, data
analysis or preparation of the manuscript.

Author Contributions: N.Z.S., A.S.P.v.T., J.P.M., J.C.N., P.H.V.,
and E.F. designed the study. J.C.N. collected data, designed the
statistical plan, and analyzed and interpreted data. N.Z.S. and
A.S.P.v.T. supervised the study and interpreted data. J.P.M. inter-
preted cognitive test results. M.A.J.L. supervised the design
of the statistical plan. J.C.N., N.Z.S., A.S.P.v.T. took the lead in
writing the manuscript. All authors discussed previous versions of
the manuscript and agreed to the submission of the final version.
A.S.P.v.T. and N.Z.S. have full access to all study data and take
responsibility for the integrity of the data and the accuracy of the
data analysis.

Additional Information
Correspondence: Jolanda C. Naafs, MD, Emma Children’s Hos-
pital, Amsterdam UMC, University of Amsterdam, department of
Pediatric Endocrinology, Meibergdreef 9, 1105 AZ Amsterdam, The
Netherlands. Email: j.c.naafs@amsterdamumc.nl.

Disclosures: The authors have nothing to disclose.

Data Availability: Datasets generated during the current study are
not publicly available but are available from the corresponding au-
thor on reasonable request.

References
1. Klein AH, Meltzer S, Kenny FM. Improved prognosis in con-
 genital hypothyroidism treated before age three months. J
Pediatr. 1972;81(5):912-915.
2. Aleksander PE, Brückner-Spieler M, Stoehr AM, et al. Mean
high-dose l-thyroxine treatment is efficient and safe to achieve
a normal IQ in young adult patients with congenital hypothy-
roidism. J Clin Endocrinol Metab. 2018;103(4):1459-1469.
3. Albert BB, Heather N, Derriak JG, et al. Neurodevelopmental and body composition outcomes in children with congenital hypothyroidism treated with high-dose initial replacement and close monitoring. *J Clin Endocrinol Metab.* 2013;98(9):3663-3670.

4. Ford G, LaFranchi SH. Screening for congenital hypothyroidism: a worldwide view of strategies. *Best Pract Res Clin Endocrinol Metab.* 2014;28(2):175-187.

5. Lanting CI, van Tijn DA, Verbeeten B Jr, Verkerk PH. Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroxine-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. *Pediatrics.* 2005;116(1):168-173.

6. Léger J, Olivieri A, Donaldson M, et al.; ESPE-PES-SLEP-JSPE-APPS-ISPAE; Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. *Horm Res Paediatr.* 2014;81(2):80-103.

7. van Tijn DA, de Vlijder JJ, Verbeeten B Jr, Verkerk PH, Vulsma T. Neonatal detection of congenital hypothyroidism of central origin. *J Clin Endocrinol Metab.* 2003;90(6):3350-3359.

8. Zwaveling-Soonawala N, van Trotsenburg AS, Verkerk PH. The severity of congenital hypothyroidism of central origin should not be underestimated. *J Clin Endocrinol Metab.* 2015;100(2):E297-E300.

9. Nebesio TD, McKenna MP, Nabhan ZM, Eugster EA. Newborn screening results in children with central hypothyroidism. *J Pediatr.* 2010;156(6):990-993.

10. Cavarzere P, Biban P, Gaudino R, et al. Diagnostic pitfalls in the assessment of congenital hypopituitarism. *J Endocrinol Invest.* 2014;37(12):1201-1209.

11. Naafs JC, Verkerk PH, Fliers E, van Trotsenburg ASP, Zwaveling-Soonawala N. Clinical and genetic characteristics of Dutch children with central congenital hypothyroidism, early detected by neonatal screening. *Eur J Endocrinol.* 2020;183(6):627-636.

12. Harding JE, Harris DL, Hegarty JE, Alsweiler JM, McKinlay CJ. An emerging evidence base for the management of neonatal hypoglycaemia. *Early Hum Dev.* 2017;104:51-56.

13. McKinlay CJ, Alsweiler JM, Anstice NS, et al.; Children With Hypoglycaemia and Their Later Development (CHYLD) Study Team. Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. *JAMA Pediatr.* 2017;171(10):972-983.

14. Naafs JC, Vendrig LM, Limpens J, et al. Cognitive outcome in congenital central hypothyroidism: a systematic review with meta-analysis of individual patient data. *Eur J Endocrinol.* 2020;182(3):351-361.

15. Baron IS, Leonberger KA. Assessment of intelligence in the preschool period. *Neuropsy chol Rev.* 2012;22(4):334-344.

16. Heinen CA, Losekoot M, Sun Y, et al. Mutations in TBL1X are associated with central hypothyroidism. *J Clin Endocrinol Metab.* 2016;101(12):4564-4573.

17. Webb EA, Dattani MT. Understanding hypopituitarism. *Paediatr Child Health.* 2015;25(7):295-301.

18. Stirois PA, Posner M, Stethens JA, et al.; Hemophilia Growth and Development Study. Quantifying practice effects in longitudinal research with the WISC-R and WAIS-R: a study of children and adolescents with hemophilia and male siblings without hemophilia. *J Pediatr Psychol.* 2002;27(2):121-131.

19. Schoemaker MM, Smits-Engelsman BC, Jongmans MJ. Psychometric properties of the movement assessment battery for children-checklist as a screening instrument for children with a developmental co-ordination disorder. *Br J Educ Psychol.* 2003;73(Pt 3):425-441.

20. Derrick B, Dobson-Mckitrick A, Toher D, White P. Test statistics for comparing two proportions with partially overlapping samples. *J Appl Quant Methods.* 2015;10(3):120-126.

21. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Software.* 2015;67(1):1-48.

22. Heinen CA, de Vries EM, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Software.* 2015;67(1):1-48.

23. Kooistra L, Laane C, Vulsma T, Schellekens JM, van der Meere JJ, Kalverboer AF. Motor and cognitive development in children with congenital hypothyroidism: a long-term evaluation of the effects of neonatal treatment. *J Pediatr.* 1994;124(6):903-909.

24. Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden MW, et al. Intellectual and motor development of young adults with congenital hypothyroidism diagnosed by neonatal screening. *J Clin Endocrinol Metab.* 2006;91(2):418-425.

25. Seo MK, Yoon JS, So CH, Lee HS, Hwang JS. Intellectual development in preschool children with early treated congenital hypothyroidism. *Ann Pediatr Endocrinol Metab.* 2017;22(2):102-107.

26. Vergier J, Castinetti F, Saveanu A, Girard N, Brue T, Reynaud R. Diagnosis of endocrine disease: pituitary stalk interruption syndrome: etiology and clinical manifestations. *Eur J Endocrinol.* 2019;181(3):R199-R209.

27. Azar-Kolakez A, Ecosse E, Dos Santos S, Léger J. All-cause and disease-specific mortality and morbidity in patients with congenital hypothyroidism treated since the neonatal period: a national population-based study. *J Clin Endocrinol Metab.* 2013;98(2):785-793.

28. Karges B, LeHeup B, Schoene E, et al. Compound heterozygous and homozygous mutations of the TSHbeta gene as a cause of congenital central hypothyroidism in Europe. *Horm Res.* 2004;62(3):149-155.

29. Joustra SD, Andela CD, Oostdijk W, et al. Mild deficits in attentional control in patients with the IGSF1 deficiency syndrome. *Clin Endocrinol (Oxf).* 2016;84(6):896-903.

30. Holdnack JA, Prifitera A, Weiss LG, Saklofske DH. Chapter 12—WISC-V and the personalized assessment approach. In: Weiss LG, Saklofske DH, Holdnack JA, Prifitera A, eds. *WISC-V Assessment and Interpretation.* Academic Press; 2016:373-413.

31. Pardo Campos ML, Musso M, Keselman A, Gruño L, Bergadá I, Chiesa A. Cognitive profiles of patients with early detected and treated congenital hypothyroidism. *Arch Argent Pediatr.* 2017;115(1):12-17.

32. Zoeller RT, Rovet J. Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. *J Neuroendocrinol.* 2004;16(10):809-818.